Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01813422
Registration number
NCT01813422
Ethics application status
Date submitted
15/03/2013
Date registered
19/03/2013
Date last updated
20/02/2019
Titles & IDs
Public title
GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound
Query!
Scientific title
A Double-blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Determine the Effects of Evolocumab (AMG 145) Treatment on Atherosclerotic Disease Burden as Measured by Intravascular Ultrasound in Subjects Undergoing Coronary Catheterization
Query!
Secondary ID [1]
0
0
2012-004208-37
Query!
Secondary ID [2]
0
0
20120153
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
GLAGOV
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Hypercholesterolemia
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Other metabolic disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Other - Evolocumab
Treatment: Drugs - Placebo
Placebo comparator: Placebo - Participants received placebo to evolocumab administered by subcutaneous injection once a month for 76 weeks.
Experimental: Evolocumab - Participants received 420 mg evolocumab administered by subcutaneous injection once a month for 76 weeks.
Treatment: Other: Evolocumab
Administered by subcutaneous injection
Treatment: Drugs: Placebo
Administered by subcutaneous injection
Query!
Intervention code [1]
0
0
Treatment: Other
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change From Baseline in Percent Atheroma Volume at Week 78
Query!
Assessment method [1]
0
0
Intravascular ultrasound (IVUS) was used to visualize the extent of atherosclerotic plaques in the coronary artery lumen. The extent of atherosclerosis was expressed as percent atheroma volume (PAV) in a = 40 mm segment of one targeted (imaged) coronary artery, calculated as the percentage of the total vessel volume occupied by atheroma.
Query!
Timepoint [1]
0
0
Baseline and week 78
Query!
Secondary outcome [1]
0
0
Change From Baseline in Total Atheroma Volume at Week 78
Query!
Assessment method [1]
0
0
Intravascular ultrasound (IVUS) was used to visualize the extent of atherosclerotic plaques in the coronary artery lumen. Total atheroma volume (TAV) in a = 40 mm segment of the targeted coronary artery was calculated as the average plaque area over the number of images that were evaluated by IVUS multiplied by the median vessel length to compensate for differences in segment length between participants.
Query!
Timepoint [1]
0
0
Baseline and week 78
Query!
Secondary outcome [2]
0
0
Percentage of Participants With Regression in Percent Atheroma Volume
Query!
Assessment method [2]
0
0
Intravascular ultrasound (IVUS) was used to visualize the extent of atherosclerotic plaques in the coronary artery lumen. The extent of atherosclerosis was expressed as percent atheroma volume (PAV) in a = 40 mm segment of one targeted (imaged) coronary artery, calculated as the percentage of the total vessel volume occupied by atheroma.
Regression in PAV was defined as any reduction from baseline in PAV.
Query!
Timepoint [2]
0
0
Baseline and week 78
Query!
Secondary outcome [3]
0
0
Percentage of Participants With Regression in Total Atheroma Volume
Query!
Assessment method [3]
0
0
Intravascular ultrasound (IVUS) was used to visualize the extent of atherosclerotic plaques in the coronary artery lumen. Total atheroma volume (TAV) in a = 40 mm segment of the targeted coronary artery was calculated as the average plaque area over the number of images that were evaluated by IVUS multiplied by the median vessel length to compensate for differences in segment length between participants.
Regression in TAV was defined as any reduction from baseline in TAV.
Query!
Timepoint [3]
0
0
Baseline and week 78
Query!
Eligibility
Key inclusion criteria
* Clinical indication for coronary angiography
* Subjects already taking statin therapy, niacin or ezetimibe at screening must have been on a stable dose for at least 4 weeks prior to screening LDL-C. Subjects not taking lipid-regulating therapy must enter the study via a lipid stabilization period. Subjects who are intolerant to statins must meet statin intolerance entry criteria
* Fasting LDL-C = 80 mg/dL (2.07 mmol/L) with or without additional risk factors, or, LDL-C = 60 -< 80 mg/dL (1.55-2.07 mmol/L) in the presence of one major or three minor risk factors
Subjects must meet the following criteria at the qualifying coronary catheterization procedure:
* Evidence of coronary heart disease (at least one lesion in a native coronary artery that has > 20% reduction in lumen diameter) or prior percutaneous intervention (PCI)
* Left main coronary artery < 50% reduction in lumen diameter by visual estimation
* Target coronary artery for IVUS must be accessible to the IVUS catheter, must not have a > 50% reduction in lumen diameter within the target segment (and at least 40 mm in length); cannot have undergone prior PCI or coronary artery bypass graft (CABG) and is not a candidate for intervention over the next 18 months. It may not be a bypass graft, bypassed vessel or culprit vessel for previous myocardial infarction (MI).
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
99
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Coronary artery bypass graft surgery < 6 weeks prior to the qualifying IVUS
* New York Heart Association (NYHA) III or IV heart failure, or last known left ventricular ejection fraction less than 30%
* Uncontrolled cardiac arrhythmia that is not controlled by medications in the 3 months prior to randomization
* Known hemorrhagic stroke
* Uncontrolled hypertension at randomization
* Fasting Triglycerides = 400 mg/dL (4.5 mmol/L) at screening
* Type 1 diabetes or poorly controlled type 2 diabetes (hemoglobin A1c [HbA1c] > 9%) at screening.
* Moderate to severe renal dysfunction (estimated glomerular filtration rate [eGFR] < 30 ml/min/1.73m²) at screening.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
18/04/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
29/07/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
970
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Research Site - Concord
Query!
Recruitment hospital [2]
0
0
Research Site - Darlinghurst
Query!
Recruitment hospital [3]
0
0
Research Site - Liverpool
Query!
Recruitment hospital [4]
0
0
Research Site - New Lambton Heights
Query!
Recruitment hospital [5]
0
0
Research Site - Chermside
Query!
Recruitment hospital [6]
0
0
Research Site - Herston
Query!
Recruitment hospital [7]
0
0
Research Site - Adelaide
Query!
Recruitment hospital [8]
0
0
Research Site - Bedford Park
Query!
Recruitment hospital [9]
0
0
Research Site - Epping
Query!
Recruitment hospital [10]
0
0
Research Site - Footscray
Query!
Recruitment hospital [11]
0
0
Research Site - Heidelberg
Query!
Recruitment hospital [12]
0
0
Research Site - Melbourne
Query!
Recruitment hospital [13]
0
0
Research Site - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2139 - Concord
Query!
Recruitment postcode(s) [2]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [3]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [4]
0
0
2305 - New Lambton Heights
Query!
Recruitment postcode(s) [5]
0
0
4032 - Chermside
Query!
Recruitment postcode(s) [6]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [7]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [8]
0
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [9]
0
0
3076 - Epping
Query!
Recruitment postcode(s) [10]
0
0
3011 - Footscray
Query!
Recruitment postcode(s) [11]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [12]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [13]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
District of Columbia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Indiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kentucky
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Louisiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Maryland
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Michigan
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Minnesota
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Missouri
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Montana
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Nebraska
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New Jersey
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New York
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
North Carolina
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
North Dakota
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Ohio
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Oklahoma
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Oregon
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Pennsylvania
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Tennessee
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Texas
Query!
Country [26]
0
0
Argentina
Query!
State/province [26]
0
0
Buenos Aires
Query!
Country [27]
0
0
Argentina
Query!
State/province [27]
0
0
Córdoba
Query!
Country [28]
0
0
Argentina
Query!
State/province [28]
0
0
Santa Fe
Query!
Country [29]
0
0
Argentina
Query!
State/province [29]
0
0
Corrientes
Query!
Country [30]
0
0
Belgium
Query!
State/province [30]
0
0
Antwerpen
Query!
Country [31]
0
0
Belgium
Query!
State/province [31]
0
0
Brussels
Query!
Country [32]
0
0
Belgium
Query!
State/province [32]
0
0
Bruxelles
Query!
Country [33]
0
0
Belgium
Query!
State/province [33]
0
0
Edegem
Query!
Country [34]
0
0
Belgium
Query!
State/province [34]
0
0
Genk
Query!
Country [35]
0
0
Belgium
Query!
State/province [35]
0
0
Gent
Query!
Country [36]
0
0
Belgium
Query!
State/province [36]
0
0
Hasselt
Query!
Country [37]
0
0
Belgium
Query!
State/province [37]
0
0
Lodelinsart
Query!
Country [38]
0
0
Brazil
Query!
State/province [38]
0
0
Espírito Santo
Query!
Country [39]
0
0
Brazil
Query!
State/province [39]
0
0
Goiás
Query!
Country [40]
0
0
Brazil
Query!
State/province [40]
0
0
Paraná
Query!
Country [41]
0
0
Brazil
Query!
State/province [41]
0
0
Rio Grande Do Sul
Query!
Country [42]
0
0
Brazil
Query!
State/province [42]
0
0
São Paulo
Query!
Country [43]
0
0
Canada
Query!
State/province [43]
0
0
Alberta
Query!
Country [44]
0
0
Canada
Query!
State/province [44]
0
0
British Columbia
Query!
Country [45]
0
0
Canada
Query!
State/province [45]
0
0
Manitoba
Query!
Country [46]
0
0
Canada
Query!
State/province [46]
0
0
New Brunswick
Query!
Country [47]
0
0
Canada
Query!
State/province [47]
0
0
Newfoundland and Labrador
Query!
Country [48]
0
0
Canada
Query!
State/province [48]
0
0
Nova Scotia
Query!
Country [49]
0
0
Canada
Query!
State/province [49]
0
0
Ontario
Query!
Country [50]
0
0
Canada
Query!
State/province [50]
0
0
Quebec
Query!
Country [51]
0
0
Chile
Query!
State/province [51]
0
0
Cautín
Query!
Country [52]
0
0
Chile
Query!
State/province [52]
0
0
Santiago
Query!
Country [53]
0
0
Czechia
Query!
State/province [53]
0
0
Brno
Query!
Country [54]
0
0
Czechia
Query!
State/province [54]
0
0
Hradec Kralove
Query!
Country [55]
0
0
Czechia
Query!
State/province [55]
0
0
Praha 2
Query!
Country [56]
0
0
Czechia
Query!
State/province [56]
0
0
Praha 4
Query!
Country [57]
0
0
Czechia
Query!
State/province [57]
0
0
Usti nad Labem
Query!
Country [58]
0
0
Czechia
Query!
State/province [58]
0
0
Zlin
Query!
Country [59]
0
0
Denmark
Query!
State/province [59]
0
0
Aarhus N
Query!
Country [60]
0
0
Denmark
Query!
State/province [60]
0
0
Odense C
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Besançon Cedex
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Chambray les Tours
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
Creteil
Query!
Country [64]
0
0
France
Query!
State/province [64]
0
0
Marseille cedex 5
Query!
Country [65]
0
0
France
Query!
State/province [65]
0
0
Paris
Query!
Country [66]
0
0
France
Query!
State/province [66]
0
0
Pessac Cedex
Query!
Country [67]
0
0
Germany
Query!
State/province [67]
0
0
Aachen
Query!
Country [68]
0
0
Germany
Query!
State/province [68]
0
0
Essen
Query!
Country [69]
0
0
Germany
Query!
State/province [69]
0
0
München
Query!
Country [70]
0
0
Germany
Query!
State/province [70]
0
0
Neuss
Query!
Country [71]
0
0
Germany
Query!
State/province [71]
0
0
Regensburg
Query!
Country [72]
0
0
Germany
Query!
State/province [72]
0
0
Ulm
Query!
Country [73]
0
0
Greece
Query!
State/province [73]
0
0
Alexandroupoli
Query!
Country [74]
0
0
Greece
Query!
State/province [74]
0
0
Athens
Query!
Country [75]
0
0
Greece
Query!
State/province [75]
0
0
Heraklion
Query!
Country [76]
0
0
Hungary
Query!
State/province [76]
0
0
Budapest
Query!
Country [77]
0
0
Hungary
Query!
State/province [77]
0
0
Debrecen
Query!
Country [78]
0
0
Hungary
Query!
State/province [78]
0
0
Pecs
Query!
Country [79]
0
0
Hungary
Query!
State/province [79]
0
0
Szeged
Query!
Country [80]
0
0
Iceland
Query!
State/province [80]
0
0
Reykjavik
Query!
Country [81]
0
0
Ireland
Query!
State/province [81]
0
0
Dublin
Query!
Country [82]
0
0
Ireland
Query!
State/province [82]
0
0
Galway
Query!
Country [83]
0
0
Israel
Query!
State/province [83]
0
0
Hadera
Query!
Country [84]
0
0
Israel
Query!
State/province [84]
0
0
Jerusalem
Query!
Country [85]
0
0
Israel
Query!
State/province [85]
0
0
Rehovot
Query!
Country [86]
0
0
Italy
Query!
State/province [86]
0
0
Novara
Query!
Country [87]
0
0
Italy
Query!
State/province [87]
0
0
Roma
Query!
Country [88]
0
0
Italy
Query!
State/province [88]
0
0
Rozzano MI
Query!
Country [89]
0
0
Italy
Query!
State/province [89]
0
0
Sesto San Giovanni (MI)
Query!
Country [90]
0
0
Italy
Query!
State/province [90]
0
0
Torino
Query!
Country [91]
0
0
Korea, Republic of
Query!
State/province [91]
0
0
Daejeon
Query!
Country [92]
0
0
Korea, Republic of
Query!
State/province [92]
0
0
Seongnam-si
Query!
Country [93]
0
0
Korea, Republic of
Query!
State/province [93]
0
0
Seoul
Query!
Country [94]
0
0
Malaysia
Query!
State/province [94]
0
0
Pahang
Query!
Country [95]
0
0
Malaysia
Query!
State/province [95]
0
0
Penang
Query!
Country [96]
0
0
Mexico
Query!
State/province [96]
0
0
Jalisco
Query!
Country [97]
0
0
Mexico
Query!
State/province [97]
0
0
Querétaro
Query!
Country [98]
0
0
Mexico
Query!
State/province [98]
0
0
San Luis Potosí
Query!
Country [99]
0
0
Mexico
Query!
State/province [99]
0
0
Sinaloa
Query!
Country [100]
0
0
Mexico
Query!
State/province [100]
0
0
Aguascalientes
Query!
Country [101]
0
0
Mexico
Query!
State/province [101]
0
0
Puebla
Query!
Country [102]
0
0
Netherlands
Query!
State/province [102]
0
0
Alkmaar
Query!
Country [103]
0
0
Netherlands
Query!
State/province [103]
0
0
Amsterdam
Query!
Country [104]
0
0
Netherlands
Query!
State/province [104]
0
0
Eindhoven
Query!
Country [105]
0
0
Netherlands
Query!
State/province [105]
0
0
Leeuwarden
Query!
Country [106]
0
0
Netherlands
Query!
State/province [106]
0
0
Nieuwegein
Query!
Country [107]
0
0
Netherlands
Query!
State/province [107]
0
0
Nijmegen
Query!
Country [108]
0
0
Netherlands
Query!
State/province [108]
0
0
Rotterdam
Query!
Country [109]
0
0
Netherlands
Query!
State/province [109]
0
0
Tilburg
Query!
Country [110]
0
0
Netherlands
Query!
State/province [110]
0
0
Utrecht
Query!
Country [111]
0
0
Netherlands
Query!
State/province [111]
0
0
Venlo
Query!
Country [112]
0
0
Netherlands
Query!
State/province [112]
0
0
Zwolle
Query!
Country [113]
0
0
Norway
Query!
State/province [113]
0
0
Oslo
Query!
Country [114]
0
0
Norway
Query!
State/province [114]
0
0
Tromso
Query!
Country [115]
0
0
Philippines
Query!
State/province [115]
0
0
Pasig City
Query!
Country [116]
0
0
Philippines
Query!
State/province [116]
0
0
Quezon City
Query!
Country [117]
0
0
Poland
Query!
State/province [117]
0
0
Chrzanow
Query!
Country [118]
0
0
Poland
Query!
State/province [118]
0
0
Kedzierzyn Kozle
Query!
Country [119]
0
0
Poland
Query!
State/province [119]
0
0
Krakow
Query!
Country [120]
0
0
Poland
Query!
State/province [120]
0
0
Lodz
Query!
Country [121]
0
0
Poland
Query!
State/province [121]
0
0
Warszawa
Query!
Country [122]
0
0
Russian Federation
Query!
State/province [122]
0
0
Kemerovo
Query!
Country [123]
0
0
Russian Federation
Query!
State/province [123]
0
0
Moscow
Query!
Country [124]
0
0
Singapore
Query!
State/province [124]
0
0
Singapore
Query!
Country [125]
0
0
South Africa
Query!
State/province [125]
0
0
Gauteng
Query!
Country [126]
0
0
South Africa
Query!
State/province [126]
0
0
Western Cape
Query!
Country [127]
0
0
Spain
Query!
State/province [127]
0
0
Andalucía
Query!
Country [128]
0
0
Spain
Query!
State/province [128]
0
0
Asturias
Query!
Country [129]
0
0
Spain
Query!
State/province [129]
0
0
Cataluña
Query!
Country [130]
0
0
Spain
Query!
State/province [130]
0
0
Galicia
Query!
Country [131]
0
0
Spain
Query!
State/province [131]
0
0
Madrid
Query!
Country [132]
0
0
Sweden
Query!
State/province [132]
0
0
Göteborg
Query!
Country [133]
0
0
Sweden
Query!
State/province [133]
0
0
Helsingborg
Query!
Country [134]
0
0
Sweden
Query!
State/province [134]
0
0
Lund
Query!
Country [135]
0
0
Sweden
Query!
State/province [135]
0
0
Solna
Query!
Country [136]
0
0
Sweden
Query!
State/province [136]
0
0
Stockholm
Query!
Country [137]
0
0
Sweden
Query!
State/province [137]
0
0
Örebro
Query!
Country [138]
0
0
Switzerland
Query!
State/province [138]
0
0
Geneva 14
Query!
Country [139]
0
0
Switzerland
Query!
State/province [139]
0
0
St. Gallen
Query!
Country [140]
0
0
Taiwan
Query!
State/province [140]
0
0
Kaohsiung
Query!
Country [141]
0
0
Taiwan
Query!
State/province [141]
0
0
New Taipei
Query!
Country [142]
0
0
Taiwan
Query!
State/province [142]
0
0
Taichung City
Query!
Country [143]
0
0
Taiwan
Query!
State/province [143]
0
0
Taipei
Query!
Country [144]
0
0
United Kingdom
Query!
State/province [144]
0
0
Newcastle Upon Tyne
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Amgen
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study will evaluate whether low-density lipoprotein (LDL-C) lowering with evolocumab (AMG 145) results in greater change from baseline in percent atheroma volume (PAV) at week 78 than placebo in adults with coronary artery disease taking lipid lowering therapy.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01813422
Query!
Trial related presentations / publications
Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016 Dec 13;316(22):2373-2384. doi: 10.1001/jama.2016.16951. Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJP, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Honda S, Shishikura D, Scherer DJ, Borgman M, Brennan DM, Wolski K, Nissen SE. Effect of Evolocumab on Coronary Plaque Composition. J Am Coll Cardiol. 2018 Oct 23;72(17):2012-2021. doi: 10.1016/j.jacc.2018.06.078. Schmidt AF, Carter JL, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020 Oct 20;10(10):CD011748. doi: 10.1002/14651858.CD011748.pub3. Puri R, Nissen SE, Somaratne R, Cho L, Kastelein JJ, Ballantyne CM, Koenig W, Anderson TJ, Yang J, Kassahun H, Wasserman SM, Scott R, Borgman M, Nicholls SJ. Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). Am Heart J. 2016 Jun;176:83-92. doi: 10.1016/j.ahj.2016.01.019. Epub 2016 Feb 17.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
MD
Query!
Address
0
0
Amgen
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01813422
Download to PDF